Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies

References

• Dalakas MC, Medscape advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507–517.
   PubMed Web of Science ®Google Scholar
• Imbach P, d'APUZZO V, Hirt A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;317(8232):1228–1231.
   Google Scholar
• Vlam L, Van Der Pol W-LL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48–58.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36(6):838–845. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=24370922
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144.
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35–46.
   PubMed Web of Science ®Google Scholar
• Hodkinson JP, Lucas M, Lee M, et al. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. Clin Exp Immunol. 2015;181(1):179–187.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Ellis L, Hadden RD, et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016;21(1):33–37. https://doi.org/http://dx.doi.org/10.1111/jns.12158
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2006;11(4):325–329.
   PubMed Web of Science ®Google Scholar
• Adrichem M, Lucke I, Vrancken A, et al. Intravenous Immunoglobulin Overtreatment in Chronic Inflammatory Demyelinating Polyneuropathy: Double-Blind Randomized Controlled Non-Inferiority Trial (IOC-TRIAL). In: PNS Annual Meeting. Genoa; 2019.
   Google Scholar
• Kaplan A, Brannagan TH. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2017;55(4):476–482. ].
   PubMed Web of Science ®Google Scholar
• Abbas A, Rajabally YA. Complications of immunoglobulin therapy and implications for treatment of inflammatory neuropathy: a review. Curr Drug Saf. 2019;14(1):3–13.
   PubMed Web of Science ®Google Scholar
• Van Den Bergh PYK, Hadden RDM, Bouche P, et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripher. J Peripher Nerv Syst. 2010;15(1):1–9.
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Yadav RK. A comparison of clinically atypical with typical chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2007;58(2):100–105.
   PubMed Web of Science ®Google Scholar
• Authority NB. Criteria for the clinical use of immunoglobulin in Australia Version 3 [Internet]. 2018. https://www.blood.gov.au/pubs/ivig/conditions-for-which-IVIg-has-an-established-therapeutic-role.html#cdn-03.
   Google Scholar
• Department of Health. Clinical guidelines for immunoglobulin use: update to second edition. 2011. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf.
   Google Scholar
• Draak THPP, Vanhoutte EK, Van Nes SI, et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology. 2014;83(23):2124–2132.
   PubMed Web of Science ®Google Scholar
• Vanhoutte EK, Faber CG, van Nes SI, et al. Rasch-built overall disability scale for multifocal motor neuropathy (MMN-RODS(©)) J Peripher Nerv Syst. 2015;20(3):296–305.
   PubMed Web of Science ®Google Scholar
• Fialho D, Chan Y-C, Allen DC, et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry. 2006;77(4):544–547.
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, Kazmi M, Ferner R, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst. 2009;14(2):118–124.
   PubMed Web of Science ®Google Scholar
• Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257(6):913–919.
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, Fokkink WJR, Brusse E, et al. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2017;22(4):425–432.
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, van Doorn PA, Vermeulen M, et al. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2013;84(8):859–861.
   PubMed Web of Science ®Google Scholar
• Bohn AB, Nederby L, Harbo T, et al. The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2011;18(6):919–924.
   PubMed Web of Science ®Google Scholar
• Allen JA, Berger M, Querol L, et al. Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies*. J Peripher Nerv Syst. 2018;23(2):78–87.
   PubMed Web of Science ®Google Scholar
• Vanhoutte EK, Faber CG, Van Nes SI, et al. Modifying the medical research council grading system through Rasch analyses. Brain. 2012;135(Pt 5):1639–1649.
   PubMedGoogle Scholar
• Merkies ISJ, Schmitz PIM, van der Meché FGA, et al. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2003;74(1):99–104. [12486276]
   PubMed Web of Science ®Google Scholar
• Park SB, Lin CSY, Burke D, et al. Activity-dependent conduction failure: molecular insights. J Peripher Nerv Syst. 2011;16(3):159–168.
   PubMed Web of Science ®Google Scholar
• Bozovic I, Kacar A, Peric S, et al. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2017;264(12):2481–2486.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, Piehl F, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589. [30171200]
   PubMed Web of Science ®Google Scholar
• van Lieverloo GGA, Wieske L, Verhamme C, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2019;24(2):187–194.
   PubMed Web of Science ®Google Scholar
• Mariotto S, Farinazzo A, Magliozzi R, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018;23(3):174–177.
   PubMed Web of Science ®Google Scholar
• Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy. Front Immunol. 2018.;9:1–13. https://doi.org/https://doi.org/10.3389/fimmu.2018.01299.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci. 2011;308(1–2):124–127.
   PubMed Web of Science ®Google Scholar
• Khalil A, Compton L, Kapoor M, et al. WED 241 Clinical relevance of regular blood monitoring in IG treatment. J Neurol Neurosurg Psychiatry. 2018;89(10):A35.1–A35.
   Web of Science ®Google Scholar
• Spillane J, Englezou C, Sarri-Gonzalez S, et al. PO207 thromboembolic risk in inflammatory neuromuscular disease patients on long-term ivig. J Neurol Neurosurg Psychiatry. 2017;88(Suppl 1):A66.2–A66.
   Google Scholar
• Markvardsen LH, Debost J-C, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836–842.
   PubMed Web of Science ®Google Scholar
• Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol. 2010;229(1–2):256–262.
   PubMed Web of Science ®Google Scholar
• Vlam L, Cats EA, Willemse E, et al. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014;85(10):1145–1148.
   PubMed Web of Science ®Google Scholar
• Misbah SA, Baumann A, Fazio R, et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst. 2011;16(2):92–97.
   PubMed Web of Science ®Google Scholar
• Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14(2):93–100.
   PubMed Web of Science ®Google Scholar
• Dacci P, Riva N, Scarlato M, et al. Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol Sci. 2010;31(6):829–831.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Wong SL, Kearney DA. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol. 2013;260(8):2052–2056.
   PubMed Web of Science ®Google Scholar
• Kokubun N, Sada T, Yuki N, et al. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement. Eur Neurol. 2013;70(1–2):65–69.
   PubMed Web of Science ®Google Scholar
• Debs R, Reach P, Cret C, et al. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients. Int J Neurosci. 2017;127(10):864–872.
   PubMed Web of Science ®Google Scholar